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A child with a central nervous system relapse  
of a facial embryonal rhabdomyosarcoma
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Rhabdomyosarcoma (RMS) is the most common type of soft tissue sarcoma in children. There are two main types 
of RMS: embryonal and alveolar (having a worse prognosis). The treatment for childhood RMS is based on surgery, 
chemotherapy and radiation. In spite of very intensive therapy, 1/3 of patients suffer a relapse. The case report presents 
a child with facial embryonal RMS with an atypical central nervous system relapse; this, despite a comprehensive 
diagnostic process, was diagnosed during the autopsy.
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Introduction 
Rhabdomyosarcoma (RMS) is the most common type 
of sarcoma among children, accounting for approximately 
3–4% of childhood cancers [1]. According to the American 
Cancer Society there are 350 new cases in the USA annu-
ally, which means about 4.3/1,000,000 children and young 
people per year, with half of them occurring below 10 years 
of age, and boys being slightly more prone [1, 2]. There are 
two main subtypes of RMS: embryonal (embryonale) and 
alveolar (alveolare). The embryonal type is the most frequent 
with usual occurrence in children below 5 years of age with 
the primary location being the head, neck and urogenital 
system. RMS alveolare in turn, occurs more often among 
older children and teenagers, usually affecting the trunk and 
limbs [2]. The prognosis in RMS depends on many factors: 
histological subtype, the stage of the disease at the moment 
of diagnosis, the location and size of the baseline lesion, 
age and sex. The treatment for childhood RMS is complex, 
being based on chemotherapy and radiation; however the 
most important role is played by the possibility of a radical 
surgical resection of the primary tumour. Almost 90% of 
patients with a localised form of the disease, achieve remis-
sion during intensive treatment, and in 1/3 of cases, there 
is a relapse of the disease, most often within 2–3 years of 
the end of treatment [3]. Depending on the stage of the 
disease, for the very high risk group, the 3-year EFS (event 
free survival) curve is 30–40%, for the high risk group it is 
50–55%, for standard risk 70–80% and for low — 90% [4].
The objective of this paper is to discuss an atypical pic-
ture of the recurrence within the   central nervous system 
(CNS) in a child with facial RMS, which, in spite of extensive 
diagnostic process was confirmed as late as the post-mor-
tem examination.
Case study 
A 6-year-old patient (a girl) was admitted for treatment 
at the Department of Pediatric Oncology, Hematology and 
Transplantology, in Poznan University of Medical Science 
in February 2013 on account of facial embryonal RMS with 
metastases to the right submandibular lymph nodes, quali-
fying for the high risk group. The primary tumour infiltrated 
the nasal passages and ethmoid bones, as well as the left 
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Figure 1. The MRI image of the spinal canal, longitudinal scan, with contrast agent, the enhancement of the spinal cord and meninges is visible
maxillary sinus and partly the sphenoid sinus; the tumour 
masses were also infiltrating the pterygopalatine fossa, cov-
ering the pharyngeal tonsils and peripharyngeal spaces. 
The child received treatment in accordance with the CWS 
2006 therapeutic regimen, currently standard in Poland; 
it comprised 9 chemotherapy cycles, radiotherapy of the 
tumour bed (aggregate dose: 50.4 Gy), and surgical treat-
ment consisting of the removal of the right submandibular 
lymph nodes  [5].
In September 2013, upon completion of the first line of 
treatment, the MRI (magnetic resonance imaging examina-
tion) of the face and neck confirmed a complete remission 
of the disease.
In mid-November 2013, the patient was re-admitted to 
the Clinic on account of loss of appetite for 4 days, hyper-
salivation and weakening of the lower limbs. The significant 
abnormalities found upon admission were: ptosis on the left 
side, a decrease of muscular strength and disorders of the 
exteroceptive sensation in the lower limbs. In laboratory 
tests, no significant abnormalities were found. 
During the following three days of hospitalisation, 
a gradually increasing paresis of the lower limbs and sphinc-
ter impairment was observed, as well as increased headaches 
and vomiting. Periodically the child was not responsive and 
drowsy. Given the above symptoms, a neuro-infection was 
suspected and wide-spectrum antibiotic therapy (Cetofaxi-
mum, Vancomycin, Ampicillin), anti-fungal (Fluconazolum) 
and anti-viral treatment (Acyclovir) were implemented. 
A diagnostic lumbar puncture was performed. The findings of 
the laboratory testing of CSF were the following: WBC 20/µL; 
protein 3084 mg/dl; glucose 34mg/dl. The culture of the 
CSF was sterile, and no presence of specific pathogens was 
confirmed in the PCR tests (Enterovirus, HSV-1, HSV-2, EBV, 
CMV, Adenovirus, Aspergillus fumigatus, Candida albicans, 
Candida glabrata, Candida crusei, Listeria monocytogenes). 
An MRI of the head, neck, face and spinal cord revealed 
the presence of extensive multilevel lesions: hyperintense 
lesions were seen on T2-weighted images. The oedema of 
the spinal cord was observed along its entire length. Upon 
administration of the contrast agent, heterogeneous en-
hancement of the spinal cord and strong enhancement of 
the meninges was observed (Fig. 1). A neurophysiological 
examination revealed axonal polyneuropathy and motor 
polyneuropathy without the involvement of the sensory 
fibres, which did not correspond to the paresis. Given the 
above symptoms, aseptic meningitis was suspected. The 
pulses of methylprednisolone were added, with a dose of 
30 mg/kg/d for 5 days, resulting in a slight improvement of 
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Figure 2. The MRI image of the head, transverse scan; T2-weighted image with the contrast agent, hyperintense foci in the cerebellum cortex are visible
the neurological condition of the child — the patient was 
logically responsive. During steroid therapy, no improve-
ment in motor and sensory disorders or with regards to 
sphincter impairment was observed. After the reduction 
of the steroid doses, on the tenth day of hospitalisation 
a fast deterioration of the general condition of the patient 
occurred and, with regards to increasing bradycardia, as well 
as prolonged episodes of apnoea, the child was transferred 
to the ICU department in a serious condition; treatment 
with methylprednisolone was continued, yet without any 
improvement of the clinical condition of the girl.
Another MRI of the head and spinal cord (performed 
10 days later) revealed a significant deterioration of the pic-
ture: numerous foci with an increased signal (T2-weight-
ed and FLAIR images) in the cerebellar cortex, both in the 
hemispheres, vermis and tonsils, which suggested an acute 
cerebellar stroke (on DWI D1000 and ADC images). On the 
supratentorial images, the ventricular system was not dilated 
and not shifted, and no supratentorial ischaemic areas were 
found (Fig. 2). The CT (computed tomography) examination 
of the head (performed two days after the previous MRI ex-
amination) revealed lesions corresponding to the ischemic 
stroke of the cerebellum; an increased volume (oedema) of 
the cerebellum with some features of increased subtentorial 
compartment in the posterior fossa of the cranium, pressure 
on the medulla oblongata with a complete stenosis of the 
cisterns of the pons and cerebellar-spinal cisterns, as well 
as thickening and heterogeneous structure and density of 
the medulla oblongata. Moreover, the loss of corticomedul-
lary differentiation in both brain hemispheres was found; 
a supratentorial dilation of the ventricular system and of the 
IV ventricle was observed. Around the lateral ventricles there 
were lesions corresponding to an active hydrocephalus (CSF 
leak). The brain CSF spaces and sulci were totally stenosed. 
Within the posterior fossa and brain stem, there was an im-
age of diffuse, systemic lesions with heterogeneous density 
with no way of differentiating the brain structures — the 
anatomical distinctions were blurred. On the twelfth day 
of treatment, the pupils were fixed and non-reactive. In the 
following days, a further deterioration of the neurological 
condition was observed. On the 15th day of hospitalisation, 
the death of the brain stem was confirmed and the child was 
confirmed dead. The post-mortem examination revealed RMS 
metastases to the cerebellum, medulla oblongata, spinal cord 
and meninges; brain oedema; the foci of the ischemic necrosis 
of the brain; tonsillar herniation into the foramen magnum.
325
Discussion
The main cause of the failures of the treatment of soft-
tissue sarcomas in children is relapse of the disease. Most 
frequently, relapses occur within 2 years from the comple-
tion of the treatment, and in the majority of patients, the 
relapse has a local character [3, 6, 7]. The prognosis, in the 
case of RMS is poor, and the probability of a general 5-year 
survival, depending on different factors, varies between 17 
and 36% [3, 6]. The primary location of RMS in the area of 
meninges and face is burdened with an exceptionally high 
relapse rate, due to the impossibility of performing a total 
resection of the tumour. At the same time, the symptoms of 
the cancer are nonspecific, which might delay an early diag-
nosis resulting in a very high stage of clinical advancement 
at its baseline and the impossibility of carrying out radical 
surgery. In the described case, with regards to the total clini-
cal and imaging remission achieved after the pre-surgical 
chemotherapy, no radical surgery was performed during the 
first line of treatment. The cause of the symptoms, which oc-
curred 9 months after the diagnosis of the embryonale RMS 
of the face, was found, in the autopsy, to be the remission of 
the disease. The involvement of the central nervous system, 
atypical either for RMS or for other soft tissue sarcomas, oc-
curs in 10% of patients with this diagnosis [8]. The lesions 
have usually a supratentorial location and solid type. The 
involvement of the spinal cord is very rare [9].  
Evaluation of the symptoms presented by the patient 
should be performed with diagnostic methods such as a 
head and face MRI (for the exclusion of local relapse), an MRI 
of the central nervous system, and, further, laboratory tests, 
blood and CSF microbiology. The differential diagnostics 
should include neuro-infection, neurotoxicity resulting from 
chemotherapy, a relapse of the core disease and neuro-
degenerative diseases.
In the case of this patient, both the local and late relapse 
were definitely excluded in imagining tests, resulting in 
a diagnostic process for infectious and neurodegenerative 
diseases. Also, the implemented treatment was targeted 
towards a disease with an infectious aetiology. The admin-
istration of methylprednisolone pulses, which transitionally 
decreased the oedema of the brain and spinal cord and also 
limited inflammation, led to the alleviation of symptoms 
and the reduction of the protein concentration in CSF; this 
misled the doctors, apparently confirming their diagnosis of 
aseptic meningitis. The post-mortem examination showed 
that the enhancement of the MRI signal within the cord and 
meninges was already a manifestation of the cancer relapse. 
Publications describe some isolated causes of the RMS 
relapse within the CNS, similar to this case, i.e. in a 4-year-
old boy with orbital RMS whose relapse was accompanied 
by the symptoms of increased intracranial pressure and 
the presence of abnormal cells in CSF [10]. Some other de-
scribed relapses within CNS concerned two patients with 
RMS primarily located in the chest, who underwent radical 
surgery and systemic and intrathecal chemotherapy [11]. 
Those patients died as a result of the diseases progression. 
Taking into consideration the above case of an atypical 
RMS relapse within the CNS as well as the quoted examples 
from literature and given both the diverse clinical symptoms 
and equivocal imaging results in the patients with primary 
diagnoses of RMS, one must consider the relapse of the core 
disease as the first cause of the occurrence of neurological 
symptoms and, in order to confirm it, a biopsy of the lesion 
must be performed followed by a verification against his-
topathological criteria.
The abbreviations in the text:
RMS — rhabdomyosarcoma
EFS — event free survival, CNS — central nervous system 
MRI — magnetic resonance imaging
CT — computed tomography
CSF — cerebro-spinal fluid 
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